TIDMIMM
RNS Number : 6918K
Immupharma PLC
27 June 2014
FOR IMMEDIATE RELEASE 27 JUNE 2014
ImmuPharma to access pioneering research in the Bordeaux region
of France
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is delighted to
provide further details on its activities in the Bordeaux region of
France, working closely with one of its key collaborators at the
CNRS*, ImmuPharma's longstanding research partner, accessing novel
drug research in the area of peptides.
One key relationship for Bordeaux is with the Institut Européen
de Chimie et Biologie (IECB) an international and interdisciplinary
research team incubator, placed under the joint authority of the
CNRS, INSERM (Institut National de la Santé et de la Recherche
Médicale)* and the University of Bordeaux*.
Through its network, IECB hosts 15 international and
multi-disciplinary research teams among them being the CNRS team of
Dr Gilles Guichard, one of the scientific founders of ImmuPharma,
and a leading researcher in peptides. Additionally, one of
ImmuPharma's fully owned subsidiaries, 'UREKA'a pharmaceutical
R&D unit, has its new internal research team based at the
IECB.
ImmuPharma recently announced at its Preliminary Results that
the long standing collaboration with the CNRS under Dr. Gilles
Guichard and UREKA had resulted in the filing of a new co-owned
patent controlling a breakthrough peptide technology called
'Urelix', allowing in essence to mimic long natural peptides
especially in the configuration used to bind their receptor and
improve their stability to enzymatic degradation (breakdown of
peptides into aminoacids) as well as greater efficacy. The first
therapeutic area being targeted is diabetes (with GLP1* and GIP* as
targets). Blocking the protein/protein interaction could also be
used in fighting viruses (blocking virus entry into cells) which
could be further investigated. The potential of this technology is
substantial and diverse and is one of the key reasons UREKA has
established its own research team (some provided from Dr.
Guichard's laboratory or from other prestigious Universities such
as ETH Zurich) and working in close collaboration with Dr. Guichard
and his CNRS team.
Within this collaboration the IECB having its incubator on the
campus of University of Bordeaux, has provided ImmuPharma with
access to state of the art laboratories and a number of
scientists.
Dr Robert Zimmer, ImmuPharma's President and Chief Scientific
commented: "We are delighted to have extended our research
capabilities in setting up our own research team within the IECB
laboratories in collaboration with the CNRS team of Dr. Gilles. We
have also filed the patents covering the unique peptide technology
platform (Urelix). The utilisation within our own premises, with
the potential financial support of the French Aquitaine Region,
will be integral to our ongoing strategy of keeping R&D costs
low while focusing more on applied research. Importantly, the new
discovery represents a powerful applied research engine to discover
innovative and powerful medicines, mirroring the success ImmuPharma
has already demonstrated with our patented peptide for
Lupuzor."
ImmuPharma will be hosting its Annual General Meeting later
today at 11:00am at the offices of Bircham Dyson Bell LLP, 50
Broadway, London, SW1H 0BL.
*See 'Notes to Editors'
For further information please contact:
+ 44 (0) 20 7152
ImmuPharma plc 4080
Dimitri Dimitriou, Chief
Executive Officer
Dr Robert Zimmer, President
and Chief Scientific Officer
Richard Warr, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD
& Broker +44 (0) 20 7886 2500
Hugh Morgan
Fred Walsh
Notes to Editors
CNRS - Centre National de la Recherche Scientifique
CNRS is Europe's largest fundamental research institution. It
was founded in 1939 and is a government-funded research
organization, under the administrative authority of France's
Ministry of Research and has over 30,000 employees and an annual
budget of over EUR3 billion. The CNRS has received many prestigious
awards and has produced 17 Nobel laureates and 11 Fields Medal
award winners.
About University of Bordeaux
University of Bordeaux is an association of higher education
institutions, recently merged, in and around Bordeaux, France. Its
current incarnation was established 21 March 2007. The University
is the largest system of higher education schools in south-western
France.
Its research activities contributes to the great medical and
scientific advances of the 21st century and structured around 5 key
disciplines: neurosciences; public health, society; fundamental
biology, with applications to medicine; integrative biology and
ecology; health technologies. Research at the University goes well
beyond the national framework and its researchers are involved in
numerous European and international programmes. In the Campus plan
for the future of University of Bordeaux, the biological health
division has been identified as one of the site's 'centres of
excellence'. This will include close collaboration with the
national research organisations (CNRS, INSERM, INRA, INRIA), with
technology device platforms and shared infrastructures, making
Bordeaux one of France's leading centres of biomedical
research.
IECB - Institut Européen de Chimie et Biologie
IECB is an international and interdisciplinary research team
incubator, placed under the joint authority of the CNRS, INSERM and
the University of Bordeaux.
It was created in 1998 with the support of the Aquitaine
Regional Council and moved in 2003 into a 6500m(2) building,
located in Pessac, on the campus of the University of Bordeaux.
Today, IECB is the largest research team incubator approved by
the "Cellule Hôtels à Projets" of the CNRS. 15 research teams,
accounting for almost 150 researchers, technicians and students,
are working on site every day.
Support services are provided to IECB teams through the
UMS3033/US001, a dedicated unit which brings together services in
administration, infrastructure and informatics as well as IECB's
technology platforms in Structural Biology and Analytical and
Preparative Techniques.
INSERM : The Institut national de la santé et de la recherche
médicale
INSERM, a French biomedical and public health research
institution was created in 1964, and is a public institution with a
scientific and technical vocation under the dual auspices of the
Ministry of Health and the Ministry of Research. It was created as
a successor to the French National Institute of Health.
INSERM consists of 339 research units, run by 6500 permanent
staff members. Eighty percent of INSERM research units are embedded
in research hospitals of French universities.
GLP-1 : Glucagon-like peptide-1 agonist
Glucagon-like peptide-1 agonistsor GLP-1 agonists are a class of
drugs for the treatment of type 2 diabetes. Glucagon-like peptide-1
(GLP-1), enhances glucose-dependent insulin secretion following its
release into the circulation from the gut. GLP-1 receptor agonists
enhance glucose-dependent insulin secretion by the pancreatic
beta-cell, suppress inappropriately elevated glucagon secretion,
and slow gastric emptying. The GLP1 target has a market potential
of more than $10bn according to an analyst report (Research and
Markets August 2011).
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCQKADDOBKDPAB
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024